Research programme: aryl N-substituted carboxamides - Active Biotech
Alternative Names: Research programme: aryl N-substituted carboxamides - OXiGENE/Active BiotechLatest Information Update: 25 Nov 2003
Price :
$50 *
At a glance
- Originator Active Biotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Inflammation; Transplant rejection
Most Recent Events
- 25 Nov 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 25 Nov 2003 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 25 Nov 2003 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)